Risk of VTE in Nonrespiratory and Respiratory Presentations of COVID-19 in Critically Ill Patients

[1]  Andrew L. Phillips,et al.  Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[2]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[3]  D. Altmann,et al.  The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? , 2021, Nature Reviews Immunology.

[4]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[5]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[6]  Suthan Srigunapalan,et al.  Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis , 2021, TH Open.

[7]  Ali I. Al-Gareeb,et al.  COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus , 2021, Frontiers in Cardiovascular Medicine.

[8]  V. Liu,et al.  Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California. , 2021, JAMA internal medicine.

[9]  P. Libby,et al.  COVID-19 is, in the end, an endothelial disease , 2020, European heart journal.

[10]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.